FOLH1 and neuroendocrine neoplasm: 177Lu-DOTA-TATE and 177Lu-DOTA-TOC are particularly effective for neuroendocrine tumors, while 177Lu-PSMA-617, 177Lu-DOTA-iPSMA, and 177Lu-PSMA I&T show significant efficacy in treating mCRPC (Table 2).